Formulation Development
TARGET DISCOVERY PLATFORM - Multi-Omics, SITESEEKER® Technology & the Future of Targeted Protein Degradation
Alberto Moreno, PhD, and Laura Butler, PhD, discuss the challenges associated with gene editing technologies, such as gene-trap, RNAi, and CRISPR technologies, as they do not directly provide functional characterization or inform on the presence of well-defined drug pockets or enzymatic activity of the target genes.
Thermo Fisher Scientific Introduces Next-Generation Unmixing Beads to Enhance Accuracy & Performance in Spectral & Conventional Flow Cytometry
Thermo Fisher Scientific has introduced Invitrogen™ UltraComp eBeads™ Spectral Unmixing Beads to improve accuracy in spectral and conventional flow cytometry. These beads help researchers more…
Orexo's AmorphOX Technology May Pave the Way for Intranasal GLP-1 Medication
Orexo AB recently announced positive pharmacokinetic in-vivo data for a powder-based intranasal semaglutide formulation developed with the AmorphOX technology. In the in-vivo study, three different…
Onco3R Therapeutics Announces Approval of First Clinical Trial Application for Novel SIK3 Inhibitor O3R-5671 in Autoimmune Diseases
Onco3R Therapeutics recently announced the approval of a Clinical Trial Application (CTA) by the Belgian regulatory authorities for its SIK3 inhibitor O3R-5671. The trial will…
MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity
MBX Biosciences, Inc. recently announced dosing of the first participant in its Phase 1 trial of MBX 4291, the company’s Precision Endocrine Peptide (PEP) glucagon-like…
Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions
Opus Genetics, Inc. recently announced the first patient has been dosed in LYNX-3, the company’s pivotal Phase 3 clinical trial evaluating Phentolamine Ophthalmic Solution 0.75%…
Regen BioPharma Explores Expanded Use of HemaXellerate for Chemotherapy-Induced Bone Marrow Suppression
Regen BioPharma, Inc. recently announced its ongoing efforts to expand the clinical development of HemaXellerate, its novel cellular therapy, to address chemotherapy-induced bone marrow suppression,…
2025 Analytical Testing e-Book - New ICH Guideline Outlines E&L Principles
In this exclusive Drug Development & Delivery e-book, Stevanato Group discusses E&L from the perspective of lyophilized products, common E&L testing challenges, how to mitigate testing risks.
Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome
Artelo Biosciences, Inc. recently announced highly encouraging interim results from its Phase 2 Cancer Appetite Recovery Study (CAReS) trial with ART27.13, the Company’s peripherally acting cannabinoid…
CG Oncology Completes Enrollment in PIVOT-006
CG Oncology, Inc. recently announced it has completed enrollment in its Phase 3, randomized, open-label PIVOT-006 study comparing adjuvant intravesical cretostimogene grenadenorepvec versus surveillance following…
BirchBioMed Announces Hamilton Health Sciences’ Centre for Burn Research in Ontario as First Clinical Trial Site for Pioneering Burns Scar Treatment
BirchBioMed Inc. recently announced Hamilton Health Sciences’ (HHS) Centre for Burn Research in Ontario, Canada, as the first contracted clinical trial site for its Phase…
Medicus Pharma Ltd. Completes Acquisition of Antev Limited
Medicus Pharma Ltd., a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, and Antev Limited, a…
Quotient Sciences & CPI to Accelerate RNA Drug Development With Joint Venture
Quotient Sciences, a leading global drug development and manufacturing accelerator, and UK technology innovation centre, CPI, have signed a memorandum of understanding (MoU) to form…
Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum
Propanc Biopharma, Inc. recently announced a plan to acquire $100 million of Ethereum over the next 12 months. The asset purchase of Ethereum will enhance…
Olema Oncology Announces New Clinical Trial Agreement With Pfizer
Olema Pharmaceuticals, Inc. recently announced a new clinical trial collaboration and supply agreement with Pfizer Inc. in metastatic breast cancer. The companies will evaluate in…
Zenas BioPharma & Royalty Pharma Enter Obexelimab Funding Agreement for up to $300 Million
Zenas BioPharma, Inc. and Royalty Pharma plc recently announced Royalty Pharma will provide up to $300 million in funding in exchange for a royalty on…
Encoded Therapeutics Announces Regenerative Medicine Advanced Therapy Designation Granted by FDA for ETX101 in SCN1A+ Dravet Syndrome
Encoded Therapeutics Inc. recently announced the US FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to ETX101 following review of preliminary seizure data from…
Step Pharma Announces First Participant Dosed in a Phase 1b Trial of Dencatistat for Essential Thrombocythaemia
Step Pharma recently announced the first participant has been dosed with its lead asset dencatistat in a phase 1b clinical trial for essential thrombocythaemia (ET).…
OMass Therapeutics Enters Exclusive Collaboration & License Agreement With Genentech
OMass Therapeutics recently announced it has entered into an exclusive collaboration and license agreement with Genentech for the rights to develop and commercialize OMass’ preclinical…
Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure & Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75
Lexicon Pharmaceuticals, Inc. recently announced a post-hoc analysis (Efficacy of Sotagliflozin Among Older Adults: A Pooled Analysis of SCORED and SOLOIST-WHF) of clinical data was…
